Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the treatment landscape across subtypes.

patients should receive corticosteroids and either interrupt or stop everolimus, depending on the severity of symptoms. What is the most troublesome side effect of mTOR inhibitors? In my opinion ...

De novo mTOR inhibitor immunosuppression versus calcineurin inhibitor immunosuppression for liver transplant recipients (Protocol). Cochrane Database of Systematic Reviews 2023, Issue 8. Art. No.: ...

The data also indicate that the wound healing issues observed in early studies with high exposure to mTOR inhibitors can be prevented with reduced exposure to both everolimus and tacrolimus in ...

WOODCLIFF LAKE, N.J., Nov. 7, 2020 /PRNewswire/ -- Eisai announced results from Study 218, a Phase 2 trial comparing the safety and efficacy of tw ...

Case reports documented mTOR inhibitor use in advanced angiomyolipomas ... defined response as ≥25% reduction in tumor volume with everolimus and defined clinically interesting activity as ...

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with ...

Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective in treating tumors harboring alterations in the mTOR pathway. Mechanisms of resistance to everolimus remain ...

"We conducted a phase I clinical trial of two anticancer agents -- the mTOR inhibitor everolimus, and pazopanib, another drug used to treat kidney cancer -- and one of our patients developed near ...

Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced ...